Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
Stellbrink HJ, Le Fevre E, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, Vourvahis M, Rinehart AR, McFadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, Heera J. Stellbrink HJ, et al. Among authors: heera j. AIDS. 2016 May 15;30(8):1229-38. doi: 10.1097/QAD.0000000000001058. AIDS. 2016. PMID: 26854810 Free PMC article. Clinical Trial.
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S. Mills A, et al. Among authors: heera j. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5. J Acquir Immune Defic Syndr. 2013. PMID: 23187936 Clinical Trial.
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Giaquinto C, Mawela MP, Chokephaibulkit K, Negra MD, Mitha IH, Fourie J, Fang A, van der Ryst E, Valluri SR, Vourvahis M, Zhang-Roper RY, Craig C, McFadyen L, Clark A, Heera J. Giaquinto C, et al. Among authors: heera j. Pediatr Infect Dis J. 2018 May;37(5):459-465. doi: 10.1097/INF.0000000000001808. Pediatr Infect Dis J. 2018. PMID: 29023357 Free PMC article.
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J. Vourvahis M, et al. Among authors: heera j. J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7. J Clin Pharmacol. 2019. PMID: 30192390 Free PMC article. Clinical Trial.
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Cooper DA, et al. Among authors: heera j. J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697. J Infect Dis. 2010. PMID: 20151839 Clinical Trial.
41 results